Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 941-453-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- migrated information: read-across from supporting substance (structural analogue or surrogate)
- Adequacy of study:
- key study
- Study period:
- 2008
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- GLP study according to OECD guideline 408 (adopted 1998). Minor restrictions: Ophthalmological examination not specifically stated in the document, but weekly investigation of eyes for mydriasis, miosis, and exophthalmos as well as histopathology of eyes after termination. Study was originally judged Klimisch 1. However, according to the "Practical guide 6: How to report read-across and categories" the maximum score for read-across is 2.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: Commission Directive 96/54/EEC, B.26
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Biofert Plusz
- IUPAC Name:
- Biofert Plusz
- Details on test material:
- -Name of test material (as cited in study report): Biofert Plusz
Details are presented in "Confidential details on test material"
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
-Source: Harlan Laboratories Ltd., CH
-Age at delivery: 7 weeks
-Weight at acclimatisation: 139 – 200 g
-Fasting period before study: No
-Housing: Groups of 5 animals in Macrolon type 4 cages
-Certified Diet ad libitum
-Tap water ad libitum
-Acclimation period: 7 days under test conditions after health examination. Only animals without any visible signs of illness were used
ENVIRONMENTAL CONDITIONS
-According to Guideline
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- water
- Details on oral exposure:
- The dose formulations were prepared weekly. Homogeneity of the test item in the vehicle was maintained during the daily administration period using a magnetic stirrer. The dose formulations were stored refrigerated in glass beakers (2 - 8°C).
Dose Volume: 10 mL/kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Results of the test item dose formulations analyses: range of 93.2 – 121.5 %. For 33 of 36 samples, the required content limit of +/- 20 % with reference to the nominal concentration was fulfilled (3 samples exceeded the upper range). All were found to be homogeneous, and all were found to be stable for four hours at room temperature and for seven days when refrigerated (2 - 8 °C).
- Duration of treatment / exposure:
- 91 days
- Frequency of treatment:
- Once daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
0, 100, 300 and 1000 mg/kg bw/d (dry mass). Daily dose levels for the liquid test product: 0, 356, 1068 and 3559 mg/kg bw/d
Basis:
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- -Dose selection rationale: Based on a 14 d dose-range-finding study. High dose level corresponds to the limit dose recommended in OECD Guideline 408
-Rationale for animal assignment: Randomisation - Positive control:
- no
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS
Yes: Twice daily
CLINICAL OBSERVATIONS
Yes: The animals were observed for clinical signs once before commencement of administration as well as twice daily on days 1 – 3 and once daily on days 4 – 91 (treatment period)
BODY WEIGHT
Yes: Body weights were recorded weekly during the acclimatization and treatment periods and before necropsy
FOOD CONSUMPTION AND COMPOUND INTAKE
Yes: The food consumption was recorded once during the acclimatization period and weekly thereafter
FOOD EFFICIENCY
Yes: The mean absolute food consumption and the mean relative food consumption of the treated rats compared with controls
OPHTHALMOSCOPIC EXAMINATION
No: However once weekly investigation of mydriasis, miosis, and exophthalmos
HAEMATOLOGY
Yes: Collection of blood from all animals (fasted) once after 13 weeks of exposure. Used anaesthetic was isoflurane. Examined parameters: According to guideline
CLINICAL CHEMISTRY
Yes: Time schedule for all animals (fasted): see haematology. Examined parameters: According to guideline
URINALYSIS
Yes: Urine was collected during the 18 hours fasting period (see haematology) into a specimen vial, using a metabolism cage. Examined parameters: According to guideline
DETAILED BEHAVIORAL OBSERVATIONS:
Yes: Once weekly (all rats): The animals were observed in their home cages, outside their home cages in a standard arena and in the hand. These observations were performed once before commencement of administration and once weekly (weeks 1 to 12) thereafter. Examined parameters: piloerection, salivation, hunched posture, ataxia, tremor/twitching, prostration, circling, spasm, hyperactivity, somnolence, increased exploration, reduced grooming, vocalisation, dyspnoea, tachypnoea, bradypnoea. Reflexes: blink, pinna, iridic light reflex, push-off (hind leg), pain response, startle/hearing, righting reflex. Other: lacrimation, limbs cyanotic, mydriasis, miosis, exophthalmos, reduced muscle tone
FUNCTIONAL OBSERVATION BATTERY
Yes: During week 13 (all animals). Relevant parameters: Grip strength and locomotor activity - Sacrifice and pathology:
- GROSS PATHOLOGY
Yes: Organ wet weights as recommended in guideline
HISTOPATHOLOGY
Yes: As recommended in guideline - Other examinations:
- no
- Statistics:
- Dunnett-test, Steel-test, Fisher's exact-test. Statistical analysis of: Body weights, clinical laboratory data, locomotor activity, grip strength, organ weights and ratios as well as macroscopic findings.
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- no effects observed
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- no effects observed
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- Even at the highest dose tested (1000 mg/kg bw) no significant adverse effects were found. There were some minor changes in investigated parameters such as haematology or clinical chemistry, however these findings were considered to be within the range of normal biological variation and therefore without toxicological relevance.
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- > 1 000 mg/kg bw/day (nominal)
- Based on:
- other: dry mass of the liquid test item
- Sex:
- male/female
- Basis for effect level:
- other: No adverse effects at the highest dose level tested (corresponds to the limit dose recommended in OECD Guideline 408)
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In a 13 week gavage study according to OECD Guideline 408 in male and female Wistar rats, no effects of toxicological relevance were detected even at the high dose level of 1000 mg/kg bw/d (related to dry mass).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.